公开(公告)号：US09428504B2

公开(公告)日：2016-08-30

申请号：US14418011

申请日：2013-07-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Carl Thibeault ,  Charles G. Clark ,  Indawati DeLucca ,  Carol Hui Hu ,  Yoon Jeon ,  Patrick Y. S. Lam ,  Jennifer X. Qiao ,  Wu Yang ,  Yufeng Wang ,  Tammy C. Wang

IPC: C07D471/10 ,  C07D519/00

CPC classification number: C07D471/10 ,  C07D519/00

Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.

公开(公告)号：US20150166538A1

公开(公告)日：2015-06-18

申请号：US14418011

申请日：2013-07-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Carl Thibeault ,  Charles G. Clark ,  Indawati DeLucca ,  Carol Hui Hu ,  Yoon Jeon ,  Patrick Y.S. Lam ,  Jennifer X. Qiao ,  Wu Yang ,  Yufeng Wang ,  Tammy C. Wang

IPC: C07D471/10 ,  C07D519/00

CPC classification number: C07D471/10 ,  C07D519/00

Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.

Abstract translation: 本发明提供式（I）化合物：如说明书中所定义和包含任何这些新化合物的组合物。 这些化合物是P2Y1受体的拮抗剂，可用作治疗和/或预防血栓栓塞障碍的药物。

公开(公告)号：US10696674B2

公开(公告)日：2020-06-30

申请号：US16315678

申请日：2017-07-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter W. Glunz ,  Indawati DeLucca ,  Andrew K. Dilger

IPC: C07D471/10 ,  C07D401/14 ,  C07D403/10 ,  C07D487/10 ,  C07D491/10

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

公开(公告)号：US10829501B2

公开(公告)日：2020-11-10

申请号：US16739363

申请日：2020-01-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Leon M. Smith, II ,  Vladimir Ladziata ,  Indawati DeLucca ,  Donald J. P. Pinto ,  Michael J. Orwat ,  Andrew K. Dilger ,  Kumar Balashanmuga Pabbisetty ,  Wu Yang ,  Scott A. Shaw ,  Peter W. Glunz ,  Manoranjan Panda

IPC: C07D513/04 ,  C07D213/64 ,  C07D231/18 ,  C07D471/04 ,  C07D471/12 ,  C07D413/12 ,  C07D401/12 ,  C07D231/54 ,  C07D401/14 ,  C07D231/12 ,  A61P15/10 ,  A61P9/10 ,  C07D239/06

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

公开(公告)号：US20190322664A1

公开(公告)日：2019-10-24

申请号：US16315678

申请日：2017-07-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter W. Glunz ,  Indawati DeLucca ,  Andrew K. Dilger

IPC: C07D471/10 ,  C07D491/10 ,  C07D487/10 ,  C07D403/10 ,  C07D401/14

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.